Research
Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol
Hajira Dambha-Miller, Ali Albasri, Sam Hodgson, Christopher Wilcox, Nazrul Islam, Shareen Khan, Paul Little and Simon Griffin
BJGP Open 2020; 4 (3): bjgpopen20X101115. DOI: https://doi.org/10.3399/bjgpopen20X101115
Hajira Dambha-Miller
1
NIHR Academic Clinical Lecturer and GP, Division of Primary Care and Population Health, University of Southampton, Southampton, UK
Ali Albasri
2
Clinical Pharmacist and Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Sam Hodgson
3
NIHR Academic Clinical Fellow, Division of Primary Care and Population Health, University of Southampton, Southampton, UK
Christopher Wilcox
3
NIHR Academic Clinical Fellow, Division of Primary Care and Population Health, University of Southampton, Southampton, UK
Nazrul Islam
4
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
5
Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK
Shareen Khan
6
Specialist Pharmacist, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Paul Little
7
Professor of Primary Care, Division of Primary Care and Population Health, University of Southampton, Southampton, UK
Simon Griffin
8
Professor of General Practice, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK
In this issue
Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol
Hajira Dambha-Miller, Ali Albasri, Sam Hodgson, Christopher Wilcox, Nazrul Islam, Shareen Khan, Paul Little, Simon Griffin
BJGP Open 2020; 4 (3): bjgpopen20X101115. DOI: 10.3399/bjgpopen20X101115
Jump to section
More in this TOC Section
Related Articles
Cited By...
Intended for Healthcare Professionals